<DOC>
	<DOCNO>NCT00347724</DOCNO>
	<brief_summary>The purpose study compare analgesic efficacy oral , once-daily tramadol ER 300 mg 200 mg placebo patient moderate severe chronic low back pain require daily analgesic treatment . The study hypothesis tramadol ER effective treatment moderate severe chronic low back pain .</brief_summary>
	<brief_title>A Study Comparing Effectiveness Safety Extended-release Tramadol Versus Placebo Treatment Chronic Low Back Pain</brief_title>
	<detailed_description>Immediate release ( IR ) tramadol demonstrate efficacy several pain condition include : obstetrical , gynecological , orthopedic , abdominal , oral surgery . The short elimination half-life IR tramadol necessitates every 4-6 hour dose order maintain optimum level analgesia chronic pain . The study medication study once-daily , extend release ( ER ) tramadol formulation . This multicenter , double-blind , randomize , placebo-controlled , parallel-group study . At Screening Visit , patient eligible study participation medical history , physical exam evaluation enter 2-7 day washout period time analgesic allow . At Visit 2 , patient pain intensity &gt; = 40 mm 100 mm visual analog scale ( VAS ) meet eligibility criterion admit 3-week , open-label , run-in period time receive tramadol ER 100 mg daily ( QD ) least 3 day . On Day 4 , dose increase tramadol ER 200 mg QD , base tolerability . Patients must maintain minimum dose tramadol 200 mg QD begin Week-2 ( Visit 3 ) ; dose may increase tramadol ER 300 mg QD Visit 3 , base tolerability . Patients must increase tramadol ER dose 300 QD begin Week - 1 ( Visit 4 ) ; dose must maintain one week . Patients pain unresponsive appropriate dose adjustment unacceptable side effect discontinue study alternative analgesic therapy initiate . Patients receive tramadol ER 300 mg QD end run-in period ( Visit 5 , Week 0 ) enter 12-week , double-blind period randomize receive tramadol ER 300 mg , tramadol ER 200 mg , placebo QD . No dose adjustment permit double-blind period study . Patients return safety efficacy evaluation Weeks 1 , 2 , 4 , 8 12 early termination . Study medication discontinue Week 12 patient return one week post-treatment visit ( Week 13 ) .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Patients history chronic low back pain &gt; = 6 month require treatment NSAIDs , acetaminophen , opioid analgesic , COX2 selective inhibitor , and/or muscle relaxant least 60 90 day preceeding screening visit ; good health determine investigator basis medical history , physical exam screen lab ; patient 's low back pain intensity measure &gt; = 40 mm visual analog scale ( VAS ) start runin peroid 27 day washout ; patient able discontinue treatment NSAIDs , COX2 selective inhibitor , tramadol , muscle relaxant , opioids , and/or analgesic 27 day washout period analgesic throughout entire study . Patients diagnosis complex regional pain syndrome , significant inflammatory pain , clinically significant active fibromyalgia ; patient history lumbar surgery chemonucleolysis ; patient undergo transcutaneous electrical nerve stimulation ( TENS ) spinal manipulation low back pain ; patient uncontrolled medical condition clinically significant condition would , investigator 's opinion , preclude study participation ; patient use analgesic agent washout could confound analgesic response .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>chronic low back pain ; chronic pain ; low back pain ; extended-release analgesia ; opioid</keyword>
</DOC>